Shanxi Ante Bio-Pharmaceutical Co., Ltd.

Primary trial objective: To evaluate the efficacy of once-daily application of 5% minoxidil foam compared to placebo in female subjects with androgenetic alopecia, with target area non-vellus hair count (TAHC) as the primary endpoint; Secondary trial objective: To evaluate the efficacy and safety of once-daily application of 5% minoxidil foam compared to placebo in female subjects with androgenetic alopecia.

Primary study objective: To evaluate the clinical efficacy equivalence of 5% minoxidil foam and ROGAINE® (5% minoxidil foam) in adult male subjects with androgenetic alopecia (AGA). Secondary study objective: To compare the safety of the test drug and the control drug in adult male subjects with androgenetic alopecia.

In healthy subjects, the pharmacokinetics of trimebutine maleate tablets (specification: 100 mg; test preparation) developed by Shanxi Zhendong Anxin Biopharmaceutical Co., Ltd. were studied under fasting and postprandial conditions, using trimebutine maleate tablets (trade name: Cerekinon®; specification: 100 mg) owned by Mitsubishi Tanabe Pharma Corporation as the reference preparation, and the bioequivalence of the test preparation and the reference preparation was evaluated. Secondary study objective: To observe the safety of oral administration of the test preparation and the reference preparation in healthy subjects.